Poor
Needs Review
Patient Risk:
Moderate
Summary
Major portions of the response are not supported by the provided FDA label excerpts (e.g., generalized anxiety disorder and detailed diarrhea frequency/severity and prevention advice). The labeling excerpts provided support only some labeled indications and that LYRICA is taken with or without food, plus that diarrhea can occur after abrupt discontinuation; the response includes additional, specific claims beyond the provided label text.
Category Scores
Accurate Statements
Lyrica (pregabalin) is used to treat fibromyalgia.
Section 1: “Management of fibromyalgia.”
Lyrica (pregabalin) is used to treat neuropathic pain.
Section 1 supports neuropathic pain indications (diabetic peripheral neuropathy, postherpetic neuralgia, and neuropathic pain associated with spinal cord injury), but the claim is non-specific.
Lyrica may cause gastrointestinal side effects, including diarrhea.
Section 5.6: after abrupt/rapid discontinuation, patients reported symptoms including “diarrhea.” (Label excerpt does not explicitly state diarrhea as a general adverse effect of ongoing therapy in provided text, but diarrhea is present in label excerpt.)
Starting Lyrica with a low dose and gradually increasing it may minimize the risk of Lyrica diarrhea.
Section 2 provides titration/dose-increase language for indications (e.g., starting dose and increase based on efficacy and tolerability), but the specific linkage to minimizing diarrhea is not supported by provided excerpt.
Taking Lyrica with food may reduce gastrointestinal upset, which may help minimize the risk of diarrhea.
Section 2/12.3: LYRICA can be taken “with or without food,” but the label excerpt does not state that taking with food reduces GI upset or diarrhea risk.
Unsupported Statements
Lyrica (pregabalin) is used to treat epilepsy.
Section 1 supports “Adjunctive therapy … for the treatment of partial-onset seizures,” not “epilepsy” as a general indication.
Lyrica (pregabalin) is used to treat generalized anxiety disorder.
Not present in provided Section 1 indications.
Research suggests pregabalin can cause diarrhea as a gastrointestinal side effect due to its mechanism of action affecting neurotransmitters and influencing gut function.
No provided label excerpt supports a mechanism-based explanation for diarrhea.
Approximately 4–11% of patients taking Lyrica experience diarrhea as a side effect.
No provided label excerpt includes this frequency range for diarrhea.
The percentage of patients experiencing diarrhea with Lyrica may vary depending on dosage, duration of treatment, and individual patient factors.
No provided label excerpt provides diarrhea incidence variability by these factors.
In most cases, Lyrica-related diarrhea is mild to moderate.
No provided label excerpt describes diarrhea severity distribution.
Lyrica diarrhea may be severe and persistent in some instances.
No provided label excerpt describes severe/persistent diarrhea as a labeled adverse reaction.
Severe, uncontrolled diarrhea while taking Lyrica can lead to dehydration.
Not stated in provided label excerpts.
Severe, uncontrolled diarrhea while taking Lyrica can lead to electrolyte imbalances.
Not stated in provided label excerpts.
Severe, uncontrolled diarrhea while taking Lyrica can lead to other complications.
Not stated in provided label excerpts.
Avoiding other medications that may contribute to diarrhea may help minimize the risk of Lyrica diarrhea.
No provided label excerpt gives guidance to avoid other medications to reduce diarrhea risk.
Staying hydrated by drinking plenty of water may help manage or minimize the risk of Lyrica diarrhea.
No provided label excerpt provides hydration advice for diarrhea management.
Contradictions
Important Omissions
If discussing adverse GI effects generally, the label excerpts provided do not include general diarrhea incidence during therapy; the response should have avoided or qualified specific incidence numbers (4–11%) and mechanistic/management claims not present in the provided label text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several specific claims (GAD indication; detailed diarrhea incidence/severity and complication prevention advice) are not supported by the provided label excerpts, which could mislead clinical decision-making. The only directly label-supported diarrhea statement in provided text relates to symptoms after abrupt/rapid discontinuation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Needs Review
Primary Issue
Includes unlabelled indication (generalized anxiety disorder) and multiple diarrhea-specific quantitative/mechanistic/severity and prevention/management claims not present in the provided FDA label excerpts.
Suggested Improvement
Restrict claims to the provided label-supported indications (e.g., neuropathic pain indications and fibromyalgia; adjunctive partial-onset seizures) and avoid providing specific diarrhea incidence/severity or mechanistic explanations unless supported by the provided label text. If referencing GI effects, cite only the label-supported statements (e.g., diarrhea reported after abrupt/rapid discontinuation in Section 5.6) and remove unsupported prevention/management advice.